Drugs / AT9283
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01431664 | Sep 2011 → Jul 2014 | leukemia | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00985868 | Sep 2009 → Jan 2016 | childhood malignant neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00443976 | Jan 2007 → Apr 2010 | non-Hodgkin lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00522990 | Sep 2006 → Apr 2009 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome +1 | Astex Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01145989 | Feb 2011 → Oct 2014 | plasma cell myeloma | NCIC Clinical Trials Group | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2010-12-01 | Astex Pharmaceuticals, Inc. | Results Encouraging Data on Astex’s Anti-Cancer Drug AT9283 to be Presented at ASH astx.com ↗
Researchers from the Massachusetts General Hospital Cancer Center, Harvard Medical School and the Dana -Farber Cancer Institute, in Boston, MA, have evaluated the activity of Astex ’s multi-targeted kinase inhibitor, AT9283, in combination with established multiple myeloma drugs and found a strong synergistic effect when AT9283 was combined with lenalidomide. |
| 2010-04-13 | Astex Pharmaceuticals, Inc. | Results Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010 astx.com ↗
Data from Astex’s collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital demonstrating the unique JAK2 inhibitory activity of Astex’s clinical stage kinase inhibitor, AT9283, supports its potential in the treatment of both myelofibrosis and multiple myeloma. |
| 2009-11-23 | Astex Pharmaceuticals, Inc. | Regulatory Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe astx.com ↗
Astex Therapeutics announced today that it has been granted orphan -drug designation by the U.S. Food and Drug Administration for AT9283, its combinatorial oncogenic kinase inhibitor, for the treatment of patients with Acute Myeloid Leukaemia (AML). |
| 2009-05-16 | Astex Pharmaceuticals, Inc. | Results Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009 astx.com ↗
Over 30% of patients derived clinical benefit from single agent treatment with AT9283. |
| 2008-05-28 | Astex Pharmaceuticals, Inc. | Results Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting astx.com ↗
This study reveals evidence of significant disease stabilisation in a proportion of patients. |
| 2008-04-08 | Astex Pharmaceuticals, Inc. | Results Astex Drug Candidates to be Presented at the 2008 AACR Annual Meeting astx.com ↗
In addition, Astex will present data which demonstrates the activity of its multi -targeted kinase inhibitor, AT9283, in Chronic Myelogenous Leukemia models, particularly cell lines and patient samples that are resistant to existing therapies such as Sprycel®, Tasigna® and Gleevec®. |
| 2007-11-29 | Astex Pharmaceuticals, Inc. | Results Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting astx.com ↗
We see preliminary evidence of the anti -leukemic activity of AT9283 at well-tolerated doses in patients with relapsed and refractory haematological malignancies, including AML and CML. |
| 2006-04-25 | Astex Pharmaceuticals, Inc. | Regulatory Astex Therapeutics announces IND approval for novel cancer drug AT9283 astx.com ↗
Astex Therapeutics, the fragment -based drug discovery and development company, today announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of its proprietary Aurora Kinase inhibitor, AT9283, for the treatment of cancer. |
All press releases naming this drug 13 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT9283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01431664 ↗ |
| Action | Inhibit | “AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B” PMID 24072436 ↗ Sep 20136“Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL495727 ↗ “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL495727 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL495727 ↗ “Tyrosine-protein kinase JAK3 inhibitor” CHEMBL495727 ↗ “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL495727 ↗ “Tyrosine-protein kinase ABL inhibitor” CHEMBL495727 ↗ |
| Modality | Small molecule | “AT9283, a small-molecule inhibitor of aurora kinases” NCT00522990 ↗ |
| Route | Intravenous | “given as a 24 hour IV infusion” NCT00443976 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL495727 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL495727 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL495727 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL495727 ↗ |
| Target | JAK2 | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL495727 ↗ |
| Target | JAK3 | “Tyrosine-protein kinase JAK3 inhibitor” CHEMBL495727 ↗ |